1. Home
  2. FRMM vs MNOV Comparison

FRMM vs MNOV Comparison

Compare FRMM & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRMM

Forum Markets Incorporated Common Stock

N/A

Current Price

$5.10

Market Cap

65.8M

Sector

Health Care

ML Signal

N/A

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.32

Market Cap

69.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRMM
MNOV
Founded
N/A
2000
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.8M
69.4M
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
FRMM
MNOV
Price
$5.10
$1.32
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.00
$7.50
AVG Volume (30 Days)
296.3K
31.7K
Earning Date
05-26-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
$183.55
N/A
Revenue Next Year
$166.48
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$1.76
$1.17
52 Week High
$5.87
$1.96

Technical Indicators

Market Signals
Indicator
FRMM
MNOV
Relative Strength Index (RSI) 55.08 48.89
Support Level $3.61 $1.30
Resistance Level $5.37 $1.54
Average True Range (ATR) 0.44 0.04
MACD -0.01 0.00
Stochastic Oscillator 52.81 70.00

Price Performance

Historical Comparison
FRMM
MNOV

About FRMM Forum Markets Incorporated Common Stock

Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: